Aggarwal Gaurav
Known title: DirectorCIK: 0001551965
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
Transaction History
| UNCY | ▼ Sell | Other | 652,900 | — | 8/25/2025 | View on chart |
| UNCY | ▼ Sell | Other | 1,400,000 | — | 2/18/2025 | View on chart |
| UNCY | ▼ Sell | Other | 5,500,000 | — | 10/9/2024 | View on chart |
| GERN | ▲ Buy | Grant | 1,970 | $0 | 12/29/2023 | View on chart |
| UNCY | ▼ Sell | Other | 3,470,152 | — | 7/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Unicycive Resubmits FDA Application Amid Securities Lawsuit
Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.
Unicycive Resubmits FDA Application Amid Securities Lawsuit. Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.